noodls browser compatibility check

The security settings of your browser are blocking the execution of scripts.

To use noodls, javascript support must be enabled. Please change your browser's security settings to enable javascript.

If you have changed your browser's security settings, you can click here.

related announcements

News

Vectra AI Inc

Vectra AI Launches Ascent to Help Partners Address the New Era of[...]
University Hospitals Health System[...]

University Hospitals Rainbow Babies & Children’s Named One of the Best[...]
City of New Brunswick, NJ

New Brunswick Library to Host Presentation on 1956 Hungarian Refugee Crisis

Healthcare

BioMarin Pharmaceutical Inc.

09/15/2026 | Press release | Distributed by Public on 09/15/2026 06:32

Material Event (Form 8-K)

Item 8.01 Other Events.

On September 15, 2026, BioMarin Pharmaceutical Inc. (BioMarin) announced its decision to discontinue development of VOXZOGO for children with Noonan syndrome. BioMarin made this decision after assessing a number of factors, including the feasibility of the study and the current treatment landscape for children with Noonan syndrome. This decision was not related to the safety or efficacy of VOXZOGO.

BioMarin uses its investor relations website (https://investors.biomarin.com) as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.

BioMarin Pharmaceutical Inc. published this content on September 15, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on September 15, 2026 at 12:32 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]

Back

View original format